anti-sirpa monoclonal antibody bi 770371
Generic: Anti-SIRPa Monoclonal Antibody BI 770371
anti-sirpa monoclonal antibody bi 770371: 1 clinical trial tracked.
anti-sirpa monoclonal antibody bi 770371 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-sirpa monoclonal antibody bi 770371, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary endpoint: Objective response (OR) with confirmation
InterventionalRandomizedopen90 targetStarted 2025-05Completion 2027-0750 sites · Australia, Brazil, Bulgaria, France…Boehringer Ingelheim